Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells 200 Shares

by · The Markets Daily

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Darin Lippoldt sold 200 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $169.56, for a total transaction of $33,912.00. Following the transaction, the insider directly owned 54,729 shares of the company’s stock, valued at approximately $9,279,849.24. This represents a 0.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Darin Lippoldt also recently made the following trade(s):

  • On Monday, June 29th, Darin Lippoldt sold 9,800 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $170.16, for a total transaction of $1,667,568.00.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ:NBIX traded down $1.46 during midday trading on Tuesday, hitting $168.54. The company’s stock had a trading volume of 1,074,857 shares, compared to its average volume of 1,187,589. The stock’s 50 day simple moving average is $152.82 and its 200 day simple moving average is $141.25. The stock has a market capitalization of $16.95 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 0.67 and a beta of 0.39. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $171.50.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Piper Sandler lifted their price target on Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Weiss Ratings raised Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 24th. Citigroup raised their price objective on shares of Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 25th. Finally, Wedbush increased their price target on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $187.52.

Check Out Our Latest Analysis on Neurocrine Biosciences

Institutional Trading of Neurocrine Biosciences

Hedge funds have recently modified their holdings of the company. Basecamp Wealth Advisors LLC increased its position in shares of Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after purchasing an additional 204 shares during the period. Pacer Advisors Inc. boosted its stake in Neurocrine Biosciences by 471.3% during the first quarter. Pacer Advisors Inc. now owns 169,230 shares of the company’s stock worth $22,294,000 after buying an additional 139,609 shares in the last quarter. Carmignac Gestion increased its holdings in Neurocrine Biosciences by 192.5% in the 1st quarter. Carmignac Gestion now owns 186,000 shares of the company’s stock valued at $24,504,000 after buying an additional 122,400 shares during the period. Defilade Capital Management L.P. bought a new stake in Neurocrine Biosciences in the 1st quarter valued at $27,656,000. Finally, Parallel Advisors LLC raised its stake in shares of Neurocrine Biosciences by 12.3% in the 1st quarter. Parallel Advisors LLC now owns 1,776 shares of the company’s stock valued at $234,000 after buying an additional 195 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

See Also